Baird R W Analyst Recommendations & Stock Picks → This Weight Loss Company Can't Make Enough Product (From Behind the Markets) (Ad) This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Baird R W. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Baird R W. Country All Countries United States(NYSE & NASDAQ) United States(All Exchanges) Canada United Kingdom Sector All Sectors Aerospace Auto/Tires/Trucks Basic Materials Business Services Computer and Technology Construction Consumer Discretionary Consumer Goods Consumer Staples Finance Industrial Products Medical Miscellaneous Multi-Sector Conglomerates Oils/Energy Retail/Wholesale Services Transportation Utilities All Market Caps Large Cap ($10B+) Medium Cap ($2B-$10B) Small Cap (<$2B) Market Cap MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.Available with a MarketBeat All Access SubscriptionMarketRank™Upgrade to All Access to use the All Ranks Filter Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.Available with a MarketBeat All Access SubscriptionMedia SentimentUpgrade to All Access to use the All Sentiments Filter Analyst consensus is the average investment recommendation among Wall Street research analysts.Available with a MarketBeat All Access SubscriptionAnalyst ConsensusUpgrade to All Access to use the All Ratings Filter Export to Excel CompanyCurrent PriceRating DateActionBrokerageAnalystRatingPrice TargetImpact on PriceDetailsActionsMREOMereo BioPharma Group$3.98-6.4%6/13/2024Upgraded byBaird R WAnalyst J. AllenStrong-BuyLowView details for Baird R W rating of Mereo BioPharma Group (NASDAQ:MREO) on 6/13/2024LXEOLexeo Therapeutics$15.64-3.8%6/13/2024Upgraded byBaird R WAnalyst B. SkorneyStrong-BuyLowView details for Baird R W rating of Lexeo Therapeutics (NASDAQ:LXEO) on 6/13/2024NGNENeurogene$30.32-24.2%6/11/2024Upgraded byBaird R WAnalyst J. BeattyStrong-BuyLowView details for Baird R W rating of Neurogene (NASDAQ:NGNE) on 6/11/2024ELVNEnliven Therapeutics$20.47-5.1%6/11/2024Upgraded byBaird R WAnalyst C. KusyStrong-BuyLowView details for Baird R W rating of Enliven Therapeutics (NASDAQ:ELVN) on 6/11/2024PWSCPowerSchool$22.35+0.2%6/7/2024Downgraded byBaird R WAnalyst J. VruwinkStrong-Buy -> HoldLowView details for Baird R W rating of PowerSchool (NYSE:PWSC) on 6/7/2024BWMNBowman Consulting Group$31.52+0.6%6/3/2024Upgraded byBaird R WAnalyst A. WittmannStrong-BuyLowView details for Baird R W rating of Bowman Consulting Group (NASDAQ:BWMN) on 6/3/2024 Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. BABoeing$174.99-1.9%6/3/2024Upgraded byBaird R WAnalyst P. ArmentStrong-BuyLowView details for Baird R W rating of Boeing (NYSE:BA) on 6/3/2024UNHUnitedHealth Group$481.05-1.7%5/30/2024Upgraded byBaird R WAnalyst M. HaStrong-BuyLowView details for Baird R W rating of UnitedHealth Group (NYSE:UNH) on 5/30/2024UHSUniversal Health Services$190.56+0.4%5/30/2024Upgraded byBaird R WAnalyst M. HaHoldLowView details for Baird R W rating of Universal Health Services (NYSE:UHS) on 5/30/2024THCTenet Healthcare$137.51+0.5%5/30/2024Upgraded byBaird R WAnalyst M. HaStrong-BuyLowView details for Baird R W rating of Tenet Healthcare (NYSE:THC) on 5/30/2024PRVAPrivia Health Group$17.13-1.0%5/30/2024Upgraded byBaird R WAnalyst M. HaStrong-BuyLowView details for Baird R W rating of Privia Health Group (NASDAQ:PRVA) on 5/30/2024OSCROscar Health$19.23+2.3%5/30/2024Upgraded byBaird R WAnalyst M. HaStrong-BuyLowView details for Baird R W rating of Oscar Health (NYSE:OSCR) on 5/30/2024MOHMolina Healthcare$305.91-0.7%5/30/2024Upgraded byBaird R WAnalyst M. HaStrong-BuyLowView details for Baird R W rating of Molina Healthcare (NYSE:MOH) on 5/30/2024HUMHumana$349.55-1.6%5/30/2024Upgraded byBaird R WAnalyst M. HaHoldLowView details for Baird R W rating of Humana (NYSE:HUM) on 5/30/2024HCAHCA Healthcare$340.65+1.5%5/30/2024Upgraded byBaird R WAnalyst M. HaStrong-BuyLowView details for Baird R W rating of HCA Healthcare (NYSE:HCA) on 5/30/2024ELVElevance Health$527.49-1.3%5/30/2024Upgraded byBaird R WAnalyst M. HaStrong-BuyLowView details for Baird R W rating of Elevance Health (NYSE:ELV) on 5/30/2024CVSCVS Health$61.02-0.1%5/30/2024Upgraded byBaird R WAnalyst M. HaHoldLowView details for Baird R W rating of CVS Health (NYSE:CVS) on 5/30/2024CNCCentene$66.39-2.7%5/30/2024Upgraded byBaird R WAnalyst M. HaHoldLowView details for Baird R W rating of Centene (NYSE:CNC) on 5/30/2024CIThe Cigna Group$334.81+0.3%5/30/2024Upgraded byBaird R WAnalyst M. HaStrong-BuyLowView details for Baird R W rating of The Cigna Group (NYSE:CI) on 5/30/2024ASTHAstrana Health$41.75+4.4%5/30/2024Upgraded byBaird R WAnalyst M. HaStrong-BuyLowView details for Baird R W rating of Astrana Health (NASDAQ:ASTH) on 5/30/2024ALHCAlignment Healthcare$7.55-4.4%5/30/2024Upgraded byBaird R WAnalyst M. HaStrong-BuyLowView details for Baird R W rating of Alignment Healthcare (NASDAQ:ALHC) on 5/30/2024AGLagilon health$6.74+1.4%5/30/2024Upgraded byBaird R WAnalyst M. HaHoldLowView details for Baird R W rating of agilon health (NYSE:AGL) on 5/30/2024WCCWESCO International$163.73-1.0%5/29/2024Downgraded byBaird R WAnalyst D. MantheyStrong-Buy -> HoldLowView details for Baird R W rating of WESCO International (NYSE:WCC) on 5/29/2024SAGESage Therapeutics$10.75-4.6%5/29/2024Upgraded byBaird R WAnalyst J. BeattyHoldLowView details for Baird R W rating of Sage Therapeutics (NASDAQ:SAGE) on 5/29/2024MSMMSC Industrial Direct$79.45+0.9%5/29/2024Downgraded byBaird R WAnalyst D. MantheyStrong-Buy -> HoldLowView details for Baird R W rating of MSC Industrial Direct (NYSE:MSM) on 5/29/2024MNMDMind Medicine (MindMed)$7.32-2.1%5/29/2024Upgraded byBaird R WAnalyst J. BeattyStrong-BuyLowView details for Baird R W rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 5/29/2024GWWW.W. Grainger$925.07+0.8%5/29/2024Downgraded byBaird R WAnalyst D. MantheyStrong-Buy -> HoldLowView details for Baird R W rating of W.W. Grainger (NYSE:GWW) on 5/29/2024SHOSunstone Hotel Investors$10.10-0.6%5/28/2024Upgraded byBaird R WAnalyst M. BellisarioStrong-BuyLowView details for Baird R W rating of Sunstone Hotel Investors (NYSE:SHO) on 5/28/2024TOSTToast$24.02+6.3%5/21/2024Downgraded byBaird R WAnalyst D. KoningStrong-Buy -> HoldLowView details for Baird R W rating of Toast (NYSE:TOST) on 5/21/2024LFUSLittelfuse$263.12+1.9%5/17/2024Upgraded byBaird R WAnalyst L. JunkHold -> Strong-BuyLowView details for Baird R W rating of Littelfuse (NASDAQ:LFUS) on 5/17/2024BMRNBioMarin Pharmaceutical$84.15-1.0%5/17/2024Downgraded byBaird R WAnalyst J. AllenStrong-Buy -> HoldLowView details for Baird R W rating of BioMarin Pharmaceutical (NASDAQ:BMRN) on 5/17/2024SQSPSquarespace$43.55-0.3%5/13/2024Downgraded byBaird R WAnalyst V. KesavabhotlaStrong-Buy -> HoldLowView details for Baird R W rating of Squarespace (NYSE:SQSP) on 5/13/2024FTREFortrea$23.34-3.0%5/14/2024Upgraded byBaird R WAnalyst E. ColdwellHold -> Strong-BuyLowView details for Baird R W rating of Fortrea (NASDAQ:FTRE) on 5/14/2024ULSUL Solutions$41.30+0.1%5/7/2024Upgraded byBaird R WAnalyst A. WittmannStrong-BuyLowView details for Baird R W rating of UL Solutions (NYSE:ULS) on 5/7/2024SLNOSoleno Therapeutics$41.90-1.4%5/10/2024Upgraded byBaird R WAnalyst B. SkorneyStrong-BuyLowView details for Baird R W rating of Soleno Therapeutics (NASDAQ:SLNO) on 5/10/2024ODFLOld Dominion Freight Line$173.30-0.4%5/8/2024Upgraded byBaird R WAnalyst G. HollandHold -> Strong-BuyLowView details for Baird R W rating of Old Dominion Freight Line (NASDAQ:ODFL) on 5/8/2024MWAMueller Water Products$17.52+0.2%5/8/2024Upgraded byBaird R WAnalyst M. HalloranHoldLowView details for Baird R W rating of Mueller Water Products (NYSE:MWA) on 5/8/2024DDOGDatadog$116.50-0.6%5/8/2024Upgraded byBaird R WAnalyst W. PowerHold -> Strong-BuyLowView details for Baird R W rating of Datadog (NASDAQ:DDOG) on 5/8/2024CTRICenturi$26.35+1.1%5/13/2024Upgraded byBaird R WAnalyst J. HaukeStrong-BuyLowView details for Baird R W rating of Centuri (NYSE:CTRI) on 5/13/2024BODIBeachbody$8.60-0.6%5/7/2024Upgraded byBaird R WAnalyst J. KompHoldLowView details for Baird R W rating of Beachbody (NYSE:BODI) on 5/7/2024This Weight Loss Company Can't Make Enough Product (Ad)A tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!Get the name of the company and their stock ticker here >>> MarketBeat Community Rating for Baird R WCommunity Ranking: 2.5 out of 5 (2.5 of 5 stars)Outperform Votes: 1,321 (Vote Outperform)Underperform Votes: 1,292 (Vote Underperform)Total Votes: 2,613MarketBeat's community ratings are surveys of what our community members think about Baird R W and other research firms. Vote "Outperform" if you believe Baird R W's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Baird R W's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days. Stock Forecasts and Research Tools Today's Ratings: U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks: Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools: Stock Ratings by Company Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks: Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
